CDEK
← All drugs Report issue

laropiprant

Small moleculeexperimental

Clinical trial activity

43 trials · 20 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
25
Phase 3
19
Phase 4
10

Earliest trial started Jul 1, 2003 (NCT00533208)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Prostanoid DP receptorANTAGONIST

    PTGDR antagonist

    Laropiprant was in Ph4 in combination with niacin to reduce blood cholesterol but drug was withdrawn due to adverse effects out weighing benefits. Laropiprant itself has no cholesterol lowering effect, but it reduces facial flushes induced by niacin (https://en.wikipedia.org/wiki/Laropiprant). Indication: Rosacea, Seasonal Allergies

Chemistry & pharmacology

Loading structure…

SMILES

CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3
Mol. weight
435.9 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • (3r)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl acetic acid
  • laropiprant
  • laropiprant
  • laropiprant
  • laropiprant
  • laropiprant
  • laropiprant
  • laropiprant
  • mk0524
  • mk0524
  • mk 0524
  • mk-0524
  • mk-0524
  • mk-0524
  • mk-0524
  • mk-0524

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01683656Phase 4Aug 1, 2012Fondation Ernest Boninchi, Swiss Heart Foundation, Swiss National Science Foundation, University of Geneva
NCT01583647Phase 1Jun 1, 2012Merck
NCT01451619Phase 1Nov 1, 2011Merck
NCT01308203Phase 4Oct 1, 2011Hospital Italiano de Buenos Aires, Merck
NCT01321034Phase 4Oct 1, 2011Instituto Aragones de Ciencias de la Salud, University of Zaragoza
NCT01414166Phase 3Sep 1, 2011Merck
NCT01391377N/AJul 1, 2011Monash University, National Health and Medical Research Council, Australia
NCT01239992Phase 4Jun 1, 2011Ludwig Maximilians University
NCT01335997Phase 3May 1, 2011Merck
NCT01274559Phase 3Mar 1, 2011Merck
NCT01294683Phase 3Feb 1, 2011Merck
NCT01126073Phase 4Sep 1, 2010University of Ljubljana
NCT01052311Phase 4Jul 1, 2010Tel Aviv University
NCT01118598Phase 4Jun 1, 2010Merck, University of Hull
NCT01054508Phase 4Jun 1, 2010University of Manchester
NCT01071525Phase 3Apr 1, 2010Technion University
NCT01012219Phase 1Nov 1, 2009Merck
NCT00961636Phase 3Oct 1, 2009Merck
NCT01010516Phase 4Oct 1, 2009University of Ioannina
NCT02153879Phase 4Feb 1, 2009Rovira i Virgili University, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders
Showing 20 of 43 trials
Page 1 / 3

Organizations

Research & Development (20)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerckFor profit333042003
Fondation Ernest BoninchiAcademic/Hospital1012012
Hospital Italiano de Buenos AiresAcademic/Hospital1112011
Instituto Aragones de Ciencias de la SaludAcademic/Hospital1112011
Ludwig Maximilians UniversityAcademic/Hospital1112011
Monash UniversityAcademic/Hospital1112011
National Health and Medical Research Council, AustraliaGovernment1012011
Rovira i Virgili UniversityAcademic/Hospital1112009
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic DisordersAcademic/Hospital1012009
Swiss Heart FoundationAcademic/Hospital1012012
Swiss National Science FoundationGovernment1012012
Technion UniversityAcademic/Hospital1112010
Tel Aviv UniversityAcademic/Hospital1112010
University of GenevaAcademic/Hospital1112012
University of HullAcademic/Hospital1112010
University of IoanninaAcademic/Hospital1112009
University of LjubljanaAcademic/Hospital1112010
University of ManchesterAcademic/Hospital1112010
University of OxfordAcademic/Hospital1112007
University of ZaragozaAcademic/Hospital1012011
20 organizations
Page 1 / 1